Tivanisiran for Dry Eye in Subjects with Sjogren's Syndrome
The purpose of this study is to compare the safety and effectiveness of tivanisiran sodium ophthalmic solution (eye drops) to placebo for treating signs and symptoms of DED in participants with a documented diagnosis of dry eye associated with Sjögren’s Syndrome.
Main Procedures Involved: Eye exam in both eyes and medical, ocular and surgical history review.
Blood draw for eligibility including Sjogren's assessment (SSA, SSB) within 6 weeks prior to the Visit 1 and safety laboratory tests
Duration of Participation: Study Duration: Approximately 3.5 to 4.5 months (includes a possible 6-week washout, a 14-day Run-In phase + 85-day double-masked active or vehicle treatment phase) total of 5 in-clinic visits.
18 to 100 years
Male or a female age18 years or older. Use of artificial tears, autologous serum tears or specific dry eye medications during the last 6 months. Diagnosed with either primary or secondary Sjogrens Syndrome as defined by the following (MUST BE CONFIRMED PRIOR TO RUN-IN) Seropositive for anti-Ro/SSA and/or anti-La/SSB antibodies AND/OR Positive salivary gland biopsy.
Treatment
Compensation Provided
Darren Gregory, MD
Protocol Number: 21-2624
More information available at ClinicalTrials.gov: NCT04819269
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers